Twist Bioscience filed disclosures with the SEC, listed its stock on Nasdaq, and received a rating upgrade from TD Cowen.

The entities involved

• Twist Bioscience →

  Biotechnology company

  • Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.Mon 08:52
• SEC →

  Slovak company

  • DHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Mon 17:57
  • The Fidelis Partnership is incorporating in Bermuda and filing for an initial public offering on the NYSE, with principal offices in London and a main office in Dublin.Mon 17:12
• TD Cowen →

  American investment bank

  • Analyst downgraded Ag Growth International Inc. due to debt management risks.Mon 12:33
  • TD Cowen raised its price target and gave a buy rating for Travere Therapeutics, Inc., while various institutional investors bought into the company.Mon 10:36
• Nasdaq →

  American fully electronic stock exchange

  • Apple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Mon 17:22
  • Vanguard Short-Term Inflation-Protected Securities ETF is disclosing its holdings to the SEC and trading on the Nasdaq electronic stock exchange.Mon 16:28

Related events

• Allient stock traded on NASDAQ and filed required disclosures with the SEC on August 18, 2026.Aug 18
• Twist Bioscience and BioLife Solutions are healthcare companies in the biotech sector listed on Nasdaq.Sep 17
• TD Cowen is managing a share offering for PMV Pharma, which has been filed with the SEC and utilizes Broadridge Financial Solutions for mailing the prospectus.Aug 31
• TD Cowen upgraded Crescent Biopharma shares to 'strong-buy', while Wedbush reiterated 'outperform', and a CEO sold shares under a 10b5-1 plan.Aug 27
• HCW Biologics Inc. filed disclosures with the SEC and its shares are listed on Nasdaq.Jun 27